1. Selvarajah V, Robertson D, Hansen L, et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney dis...
24. Tonneijck L, Muskiet MHA, Blijdorp CJ, et al.. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am J Physiol Renal Physiol 2019...
While the studies supporting these benefits were not initially focused on kidney health and included patients with low kidney risk, they suggest a link between GLP-1 RAs treatment and kidney protection, especially for type 2 diabetes patients with CKD18. Building upon these findings, we conducted ...
24. Tonneijck L, Muskiet MHA, Blijdorp CJ, et al.. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am J Physiol Renal Physiol 2019;316:F231-40. 25. Tonneijck L, Smits MM, Muskiet MHA, et al.. Acute...
Composite CV outcomes were also lower with the use of a GLP-1 receptor agonist (OR, 0.86 [95% CI, 0.74-0.99],P=0.03;I2=40.3%). Sensitivity analyses restricted to human GLP-1 backbone agents showed enhanced benefits. Inconsistent kidney outcome definitions, focus on diabetic populations in ...
关键词: 司美格鲁肽;2 型糖尿病;胰高血糖素样肽-1 受体激动剂;卫生技术评估;不良反应 中图分类号:R977 文献标志码:A 文章编号: 1674-6376(2024)10-2377-11 DOI:10.7501/j.issn.1674-6376.2024.10.018 Health technology assessment between weekly semaglutide and other GLP-1 receptor agonists on type 2 ...
Suspected clinical impacts of GLP-1RAs, SGLT2is, and finerenone oncardiovascular and kidney outcomes. CV, cardiovascular; GLP-1RA, glucagon-like peptide-1 receptor agonist; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MI, myocardial inf...
These beneficial effects of GLP-1RA on MACE are independent of many variable including the presence of established CV disease at baseline, the structural basis of GLP-1RA (exendin-4 based agonists vs. human GLP-1- based molecules), the daily or weekly administration of the agonist, baseline ...
Don’t like injections?Rybelsusis an oral version of semaglutide used for Type 2 diabetes. Currently, it's the only medication in the GLP-1 receptor agonist class that isn’t injected. Rybelsus is taken by mouthonce daily. To get the best results, take itfirst thing in the morningwith no...
A. et al. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug Alcohol Depend. 221, 108614 (2021). CAS PubMed PubMed Central Google Scholar Dixit, T. S., Sharma, A. N., Lucot, J...